R. Brentjens

Oncology · 2002–2019

A researcher in the Science corpus: 13 papers; trusts 10 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 214 citations into it; #581 of 1,698 by trust here, #138 by citations
• Immunology — 136 citations into it; #1,709 of 2,160 by trust here, #397 by citations
• Biomedical Engineering — 21 citations into it

Whom R. Brentjens trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Rosenberg
2. R. Morgan
3. J. Kochenderfer
4. D. Porter

Who trusts R. Brentjens overall

1. Jennifer N. Brudno
2. C. Dunbar
3. Michel Sadelain
4. J. Kochenderfer
5. S. Maude
6. Jang-Hwan Cho
7. K. High
8. I. Rivière
9. Yiping Yang
10. Robert C. Sterner

Papers from R. Brentjens's perspective

Ordered by how strongly the researchers R. Brentjens trusts endorse each paper. Same corpus, a different order for every researcher.

1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
3. The basic principles of chimeric antigen receptor (CAR) design (Cancer Discovery)
4. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (Journal of Clinical Investigation)
5. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. (Advances in Immunology)
6. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (Cancer Discovery)
7. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (Nature Medicine)
8. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (Nature Reviews Clinical Oncology)
9. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with… (Blood)
10. C-reactive protein: a critical update. (Journal of Clinical Investigation)

Their papers

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (2014) — 2,346 citations
• Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. (2012) — 651 citations
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019) — 1,264 citations
• Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (2018) — 2,147 citations
• Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018) — 722 citations
• Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo (2018) — 723 citations
• Toxicity and management in CAR T-cell therapy (2016) — 839 citations
• The future of cancer treatment: immunomodulation, CARs and combination immunotherapy (2016) — 1,105 citations
• CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (2013) — 1,977 citations
• The basic principles of chimeric antigen receptor (CAR) design (2013) — 1,379 citations
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. (2011) — 1,290 citations
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 (2003) — 669 citations
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor (2002) — 745 citations